Incyte (NASDAQ:INCY) and Protalex (OTCMKTS:PRTX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.
This table compares Incyte and Protalex’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Incyte has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500. Comparatively, Protalex has a beta of -0.27, indicating that its share price is 127% less volatile than the S&P 500.
Insider & Institutional Ownership
91.6% of Incyte shares are held by institutional investors. Comparatively, 0.2% of Protalex shares are held by institutional investors. 17.1% of Incyte shares are held by insiders. Comparatively, 80.0% of Protalex shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Incyte and Protalex’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Incyte||$1.88 billion||8.42||$109.49 million||$0.82||90.20|
Incyte has higher revenue and earnings than Protalex.
This is a summary of current ratings and recommmendations for Incyte and Protalex, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Incyte presently has a consensus target price of $92.41, indicating a potential upside of 24.94%. Given Incyte’s higher possible upside, research analysts plainly believe Incyte is more favorable than Protalex.
Incyte beats Protalex on 10 of the 11 factors compared between the two stocks.
Incyte Company Profile
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naïve acute and chronic GVHD, as well as Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC); and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome, as well as a pivotal program for solid tumors with driver activations of FGF/FGFR. Further, it is involved in developing INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. Additionally, the company develops Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Syros Pharmaceuticals, Inc.; and Innovent Biologics, Inc., as well as BriaCell Therapeutics Corp. for treating cancer. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Protalex Company Profile
Protalex, Inc. focuses on the development of biopharmaceutical drugs for treating autoimmune and inflammatory diseases in the United States. The company targets a range of autoimmune diseases, such as rheumatoid arthritis (RA), immune thrombocytopenia (ITP), psoriasis, myasthenia gravis, chronic idiopathic demyelinating polyneuropathy, and pemphigus. Its lead product candidate is PRTX-100, an immunomodulatory therapy, a highly-purified form of staphylococcal protein A, which is in Phase I/II open-label, dose-escalating study for the treatment of patients with persistent/chronic ITP; and Phase 1b clinical trial for the treatment of RA on methotrexate or leflunomide. The company was founded in 1999 and is based in Florham Park, New Jersey.
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.